(Q58231296)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Nicoletta Brunello

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

J M Kane

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

A C Altamura

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J L Ayuso Gutierrez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

W W Fleischhacker

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

W Gaebel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J Gerlach

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J D Guelfi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

W Kissling

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Y D Lapierre

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

E Lindström

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J Mendlewicz

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

G Racagni

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

L S Carulla

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

N R Schooler

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

language of work or name

English

0 references

publication date

1 February 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

European Neuropsychopharmacology

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

55-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Report on the fifth consensus conference: methodology of long-term clinical trials in psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Long-term depot antipsychotics. A risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Technique for injecting long-acting neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Prognosis in schizophrenia. A ten-year follow-up of first admissions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Influence of Family Life on the Course of Schizophrenic Disorders: A Replication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Early Intervention, Time-limited, Targeted Pharmacotherapy of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

A comparative trial of pharmacologic strategies in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Measurement of therapeutic response in schizophrenia. A critical survey

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Depot antipsychotic drugs. Place in therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Suicide among schizophrenics. Who is at risk?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Effects of smoking on fluphenazine clearance in psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Review of rapid urine tests for phenothiazine and related drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Relapse in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Intermittent vs maintenance medication in schizophrenia. Two-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

1 reference

7 January 2021

Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

1 reference

7 January 2021

Family Attitudes and Patient Social Adjustment in a Longitudinal Study of Outpatient Schizophrenics Receiving Low-Dose Neuroleptics: The Family’s View

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

The effects of clozapine on tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Costs and benefits of two doses of fluphenazine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

The role of dosage and plasma levels in neuroleptic relapse prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Schizophrenia. A follow-up study of the results of five forms of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Quality of life after psychiatric rehabilitation: the clients' perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Prospective study of tardive dyskinesia incidence in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long acting injectable neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Emotional family atmosphere and relapse: investigations on the role of relapse definition, duration of illness and resignation of relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Poor neuroleptic response in acutely exacerbated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

The prevalence and costs of psychiatric disorders and learning disabilities.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

Rating of medication influences (ROMI) scale in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900045-X

7 January 2021

10.1016/S0924-977X(97)00045-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9452941%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference